1. Home
  2. KVYO vs ACAD Comparison

KVYO vs ACAD Comparison

Compare KVYO & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Klaviyo Inc. Series A

KVYO

Klaviyo Inc. Series A

N/A

Current Price

$17.85

Market Cap

5.3B

Sector

N/A

ML Signal

N/A

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.87

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KVYO
ACAD
Founded
2012
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3B
4.3B
IPO Year
2023
2000

Fundamental Metrics

Financial Performance
Metric
KVYO
ACAD
Price
$17.85
$25.87
Analyst Decision
Strong Buy
Buy
Analyst Count
21
22
Target Price
$34.48
$30.55
AVG Volume (30 Days)
3.4M
1.3M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
35.29
69.12
EPS
0.03
0.02
Revenue
$1,234,019,000.00
$726,437,000.00
Revenue This Year
$24.47
$18.80
Revenue Next Year
$19.66
$11.70
P/E Ratio
$611.67
$1,327.00
Revenue Growth
31.63
40.45
52 Week Low
$12.53
$19.69
52 Week High
$36.76
$28.35

Technical Indicators

Market Signals
Indicator
KVYO
ACAD
Relative Strength Index (RSI) 57.52 54.10
Support Level $17.48 $25.00
Resistance Level $18.54 $27.79
Average True Range (ATR) 1.09 0.75
MACD 0.09 -0.08
Stochastic Oscillator 63.39 52.73

Price Performance

Historical Comparison
KVYO
ACAD

About KVYO Klaviyo Inc. Series A

Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: